专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US08574575B2 RS7 antibodies 有权
公开(公告)号：US08574575B2
公开(公告)日：2013-11-05
申请号：US13293608
申请日：2011-11-10
申请人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
发明人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
IPC分类号： A61K39/395
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

22. 发明授权

US08367037B2 Anti-CD74 immunoconjugates and methods of use 有权
标题翻译：抗CD74免疫缀合物及其使用方法
公开(公告)号：US08367037B2
公开(公告)日：2013-02-05
申请号：US13347934
申请日：2012-01-11
申请人： John C. Byrd , David M. Goldenberg , Hans J. Hansen
发明人： John C. Byrd , David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K51/00 , C07K16/00
CPC分类号： A61K47/48823 , A61K39/395 , A61K47/6907 , A61K47/6913 , A61K51/1234 , A61K2039/505 , C07K16/2803 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/565 , C07K2317/73 , G01N33/574 , G01N2333/70596 , G01N2800/245 , A61K2300/00
摘要： Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.
摘要翻译：公开了包含抗CD74免疫偶联物和任选的治疗和/或诊断剂的组合物。在优选的实施方案中，免疫偶联物包含缀合至脂质体或胶束的一种或多种抗CD74抗体或其抗原结合片段。还公开了在诊断和治疗过程中制备免疫缀合物和使用免疫缀合物的方法。在某些优选实施方案中，治疗方法包括向具有表达CD74的疾病的受试者施用抗CD74免疫偶联物，从而诱导表达CD74的细胞的凋亡。在更优选的实施方案中，CD74免疫缀合物能够在不存在任何其它治疗剂的情况下诱导细胞死亡，尽管可以任选地在施用抗CD74免疫缀合物之前，之后或之后施用这些试剂。组合物可以是用于施用抗CD74免疫缀合物或组合物的试剂盒的一部分。

23. 发明申请

US20120141372A1 RS7 Antibodies 有权
标题翻译： RS7抗体
公开(公告)号：US20120141372A1
公开(公告)日：2012-06-07
申请号：US13293608
申请日：2011-11-10
申请人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
发明人： Serengulam V. Govindan , Zhengxing Qu , Hans J. Hansen , David M. Goldenberg
IPC分类号： A61K39/395 , A61P31/00 , A61P37/02 , A61K51/10 , A61P35/00
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
摘要翻译：本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

24. 发明申请

US20120063993A1 THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES 有权
标题翻译：治疗与诊断联合使用多重抗体
公开(公告)号：US20120063993A1
公开(公告)日：2012-03-15
申请号：US12138065
申请日：2008-06-12
申请人： William J. McBride , David M. Goldenberg , Carl Noren , Hans J. Hansen
发明人： William J. McBride , David M. Goldenberg , Carl Noren , Hans J. Hansen
IPC分类号： A61K51/00 , C07K7/02 , C12N9/00 , A61K9/127 , A61K38/20 , A61K38/21 , A61K38/19 , A61K49/00 , A61P9/00 , A61P31/00 , A61P37/02 , A61P35/00 , A61P3/00 , A61P25/00 , A61P31/04 , A61P31/10 , A61P33/00 , A61P33/02 , A61P35/02 , A61K39/395 , B82Y5/00
CPC分类号： A61K51/0497 , A61K47/665 , A61K51/04 , A61K51/0455 , A61K51/048 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K5/06078 , C07K5/1013 , C07K5/1016 , C07K5/1019 , C07K7/06 , C07K16/18 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K16/468 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.
摘要翻译：公开了包含两个或多个通过间隔物或载体缀合的半抗原的化合物。半抗原可以包括二亚乙基三胺五乙酸（DTPA），组氨酰胺 - 琥珀酰 - 谷氨酰胺（HSG）或DTPA和HSG的组合。化合物还包括效应分子，其可以与一个或多个半抗原，间隔物/载体或两者结合。效应分子可以通过多个键连接，包括酯键，亚氨基键，氨基键，硫键，硫代缩氨基脲键，缩氨基脲键，肟键，醚键或这些键的组合。还公开了合成化合物的化合物和/或前体的方法。

25. 发明授权

US08062636B2 Antibody therapy 有权
标题翻译：抗体治疗
公开(公告)号：US08062636B2
公开(公告)日：2011-11-22
申请号：US13030204
申请日：2011-02-18
申请人： David M. Goldenberg , Hans J. Hansen
发明人： David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K31/437 , A61K31/4545 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/655 , A61K31/675 , A61K31/704 , A61K38/164 , A61K38/168 , A61K38/1816 , A61K38/191 , A61K38/193 , A61K38/196 , A61K38/20 , A61K38/217 , A61K51/1045 , A61K51/1048 , A61K51/1096 , A61K2039/505 , C07K16/3007 , C07K2317/24 , A61K2300/00
摘要： The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
摘要翻译：本发明提供了包含裸体人源化，嵌合和人抗CEA抗体和治疗剂的组合物，其可用于治疗表达CEA的癌症和其它疾病，以及使用该组合物的治疗方法。

26. 发明申请

US20110195023A1 Internalizing Anti-CD74 Antibodies and Methods of Use 审中-公开
公开(公告)号：US20110195023A1
公开(公告)日：2011-08-11
申请号：US13047515
申请日：2011-03-14
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395 , A61K51/10 , A61K38/19 , A61K38/21 , A61K38/20 , A61P37/02 , A61P37/06 , A61P17/00 , A61P3/10 , A61P25/14
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

27. 发明申请

US20110189085A1 Antibody Therapy 有权
标题翻译：抗体治疗
公开(公告)号：US20110189085A1
公开(公告)日：2011-08-04
申请号：US13030204
申请日：2011-02-18
申请人： David M. Goldenberg , Hans J. Hansen
发明人： David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K51/00 , A61K39/395 , A61K38/19 , A61K38/21 , A61K38/20 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/437 , A61K31/4545 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/655 , A61K31/675 , A61K31/704 , A61K38/164 , A61K38/168 , A61K38/1816 , A61K38/191 , A61K38/193 , A61K38/196 , A61K38/20 , A61K38/217 , A61K51/1045 , A61K51/1048 , A61K51/1096 , A61K2039/505 , C07K16/3007 , C07K2317/24 , A61K2300/00
摘要： The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
摘要翻译：本发明提供了包含裸体人源化，嵌合和人抗CEA抗体和治疗剂的组合物，其可用于治疗表达CEA的癌症和其它疾病，以及使用该组合物的治疗方法。

28. 发明授权

US07914787B2 Production and use of novel peptide-based agents with bispecific antibodies 有权
标题翻译：用双特异性抗体生产和使用新的基于肽的试剂
公开(公告)号：US07914787B2
公开(公告)日：2011-03-29
申请号：US12474665
申请日：2009-05-29
申请人： David M. Goldenberg , Hans J. Hansen , William J. McBride
发明人： David M. Goldenberg , Hans J. Hansen , William J. McBride
IPC分类号： A61K39/395 , A61K38/04 , C07K16/46 , C07K7/00
CPC分类号： A61K51/1048 , A61K47/665 , A61K47/6879 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K5/0215 , C07K5/1016 , C07K5/1019 , C07K7/06 , C07K16/18 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K16/468 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
摘要翻译：本发明涉及具有特异性结合目标组织的至少一个臂的特异性抗体或抗体片段以及特异性结合可靶向构建体的至少一个其他臂。可靶向构建体包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。可靶向构建物还包含一种或多种治疗剂或诊断剂或酶。本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。

29. 发明授权

US07902338B2 Anti-CD19 antibodies 有权
标题翻译：抗CD19抗体
公开(公告)号：US07902338B2
公开(公告)日：2011-03-08
申请号：US12266999
申请日：2008-11-07
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： C07K16/00 , C07K17/00 , C12P21/08
CPC分类号： C07K16/2803 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1069 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/283 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/92
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.
摘要翻译：本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。在更具体的实施方案中，人源化抗CD19抗体可以包含设计用于改善蛋白质稳定性，抗体结合和/或表达水平的一个或多个框架区氨基酸取代。在特别优选的实施方案中，取代包括在hA19 VH序列的人框架区中的Kabat残基91处用丝氨酸取代苯丙氨酸。

30. 发明申请

US20100284906A1 Internalizing Anti-CD74 Antibodies and Methods of Use 审中-公开
公开(公告)号：US20100284906A1
公开(公告)日：2010-11-11
申请号：US12791418
申请日：2010-06-01
申请人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K38/20 , A61K39/395 , A61K51/00 , A61K38/21 , A61P35/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式